High dose of psilocybin effective for treatment‐resistant depression
The Brown University Psychopharmacology Update December 27, 2022 DOI: 10.1002/pu.30970 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Phase 2b trial Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg, 10 mg, 1 mg |
| Duration | 3-week follow-up |
| Topics | Depression Psilocybin |
| Keywords | Adverse effect Depression economics Hallucinogen Pharmacology Cognition |
| Key findings | A single 25-mg dose of psilocybin significantly improved depressive symptoms at 3 weeks compared to a 1-mg control dose, while a 10-mg dose did not. |
Abstract
Adults with treatment‐resistant depression who received a single 25‐mg dose of psilocybin saw significant improvement in depressive symptoms relative to a control dose at 3 weeks, a Phase 2b trial has found. A smaller 10‐mg dose of psilocybin did not result in significant improvement over the control dose of 1 mg, and adverse events were common in both of the higher‐dose groups. Study results were published in the Nov. 3, 2022 issue of The New England Journal of Medicine .
Comparable studies
Other non-randomized and open-label trials on psilocybin for depression, most cited first.